CDKN2C and neoplasm: Our results clearly confirmed a major alteration in both proliferation control, with either loss of suppressor (TP53, CDKN2C, RB1) or acquisition of activator (BRAF, RAS) and in tumor suppression/drug response (TP53, FAM46C), as in most if not all cancers [43].